Patents by Inventor Mary J. Barry

Mary J. Barry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-Th1 cytokine therapy
    Patent number: 6183951
    Abstract: The present invention provides methods based on serological and genetic markers for diagnosing clinical subtypes of Crohn's disease (CD) having characteristic responsiveness to anti-Th1 cytokine therapy. In the methods of the inventions the presence of perinuclear anti-neutrophil antibody (pANCA), the presence of the TNFa10b4c1d3e3 haplotype or the presence TNFa11b4c1d3e3 haplotype each are independently diagnostic of a clinical subtype of CD having an inferior clinical response to anti-Th1 cytokine therapy. In addition, the presence of the homozygous TNF-&bgr; 1111 haplotype involving the TNFc, aa13L, aa26 and NcoI loci is independently diagnostic of a clinical subtype of CD having an inferior clinical response to anti-Th1 cytokine therapy. The presence of speckling anti-pan polymorphonuclear antibody (SAPPA) is diagnostic of a clinical subtype of CD having a superior clinical response to anti-Th1 cytokine therapy.
    Type: Grant
    Filed: May 12, 1997
    Date of Patent: February 6, 2001
    Assignee: Prometheus Laboratories, Inc.
    Inventors: Scott E. Plevy, Stephan R. Targan, Kent Taylor, Mary J. Barry
  • Methods of diagnosing clinical subtypes of crohn's disease
    Patent number: 5932429
    Abstract: Provided herein is a method of diagnosing a clinical subtype of Crohn's disease (CD) by determining whether perinuclear anti-neutrophil antibody (pANCA) is present in a patient with CD, where the presence of pANCA indicates a clinical subtype of CD with features of ulcerative colitis (UC). Also provided is a method of diagnosing a clinical subtype of Crohn's disease in a patient with CD by determining whether pANCA or speckling anti-pan polymorphonuclear antibody (SAPPA) is present in the patient with CD, where the presence of pANCA indicates a clinical subtype of CD with features of ulcerative colitis and where the presence of SAPPA indicates a clinical subtype of CD having perforating, fistulizing or small bowel obstructive disease.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: August 3, 1999
    Assignees: Cedars-Sinai Medical Center, Prometheus Laboratories Inc.
    Inventors: Stephan R. Targan, Eric A. Vasiliauskas, Scott E. Plevy, Mary J. Barry